Amylin analogue
What is Cagrilintide?
A long-acting acylated amylin analogue (AM833), studied on its own and in combination with GLP-1 compounds.
- Class
- Amylin receptor agonist
- Also known as
- AM833
- Type
- Acylated amylin analogue
- Research stage
- Clinical trials; not an approved medicine
01 · Classification
What it is
Amylin is a hormone released alongside insulin by pancreatic beta cells. Cagrilintide is a modified, long-acting version of amylin, engineered with a fatty-acid chain so it lasts much longer than the native hormone in study models.
It is a non-selective agonist that acts at both amylin receptors and the related calcitonin receptor.
02 · Mechanisms
What has been studied
- Amylin receptors (AMY1–3): receptor complexes formed by the calcitonin receptor and RAMP proteins, studied for satiety signalling in the hindbrain.
- Calcitonin receptor: cagrilintide also activates this receptor, which is part of why it is described as a dual amylin/calcitonin agonist.
- Combination research: much of the published work pairs it with a GLP-1 agonist to study complementary pathways.
03 · Evidence
Where the research is
Phase 2 and phase 3 trials have been published or are under way. It is not approved for any use in Australia.
04 · Primary sources
Read the literature
Search the primary research record directly rather than relying on summaries, including this one.
Research use only
Supplied strictly for laboratory and educational research. Not a therapeutic good, not for human or veterinary use, and not evaluated by the TGA. This overview is not medical advice and gives no dosing or administration guidance.
